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Menopause is a consequence of the normal aging process in women. This fact implies that the physiological and biochemical
alterationsresultingfrommenopauseoftenblurwiththosefromtheagingprocess.Itisthoughtthatmenopauseinwomenpresents
a higher risk for cardiovascular disease although the precise mechanism is still under discussion. The postmenopause lipid proﬁle
is clearly altered, which can present a risk factor for cardiovascular disease. Due to the role of mitochondria in fatty acid oxidation,
alterations of the lipid proﬁle in the menopausal women will also inﬂuence mitochondrial fatty acid oxidation ﬂuxes in several
organs. In this paper, we propose that alterations of mitochondrial bioenergetics in the heart, consequence from normal aging
and/or from the menopausal process, result in decreased fatty acid oxidation and accumulation of fatty acid intermediates in the
cardiomyocyte cytosol, resulting in lipotoxicity and increasing the cardiovascular risk in the menopausal women.
1. Menopause: A Burden for Aging Women
Menopauseisoneofthemostcriticalperiodsinwomen’slife.
Although being a natural biological process that occurs with
aging, physiological alterations observed during this period
can be challenging. Caused by a reduced secretion of ovarian
hormones estrogen and progesterone after depletion of the
storage of ovarian follicles, menopause deﬁnes the end of
women menstrual cycle and their natural fertility. On aver-
age, spontaneous or natural menopause occurs around the
early 50s and is conﬁrmed after 12 months of nonpatholog-
ical amenorrhoea. However, when premature ovarian failure
(POF) occurs before the 40s due to pathological causes, an
early or premature menopause can be induced, which is thus
disconnected from the aging process properly said. When
a bilateral oophorectomy is necessary, menopause occurs
immediately without women experiencing the gradual tran-
sition of perimenopause. Chemotherapy can also provoke a
permanent damage in ovaries and induces menopause per se
[1]. Women who experience an early menopause are more
susceptible to certain health problems, such as osteoporosis
and heart diseases, since they spend more time in their lives
without the beneﬁts of estrogens. POF can also be temporary
(temporary menopause) induced by high levels of stress,
excessive exercising and/or dieting, and by medications used
to treat ﬁbroids [2] and endometriosis [3]. However, as soon
as women adopt a healthier life style or stop medication,
the ovaries may resume normal production of hormones.
Normally, menopausal transition or perimenopause starts
around mid-to-late 40s and persists several years before the
last menstrual period, normally for 4-5 years (Figure 1).
Smoking and genetic background are two factors that can
inﬂuence the timing of spontaneous menopause. Normally,
smokers can reach menopause earlier than nonsmokers [4].
During perimenopause, levels of estrogen and progesterone
start gradually to decline and menstrual periods become
irregular. Since sex hormones are physiologically important
to maintain the health and normal functioning of several2 Journal of Lipids
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Figure 1: Women reproductive stages during aging: from menarche to postmenopausal. Time line represents only an average for the normal
age. More details can be found in the text.
organs, such as the heart, liver, brain, and bone, hormonal
changes observed during this menopausal transition may
induce several chronic medical conditions [5]. All women
experience menopause, but diﬀerent women may cope with
diﬀerentsymptoms.Thevariationofmenopausephenotypes
around the world and in diﬀerent ethnic groups suggests
both cultural and genetic inﬂuences [6, 7]. Menstrual irreg-
ularities, vaginal atrophy, and vasomotor instability are the
most frequentmenopausal symptoms that have been directly
related with the decreased levels of female sex hormones [8].
Menopause-associatedvasomotorsymptoms(alsoknown
as hot ﬂashes) include spontaneous feeling of warmth, usu-
ally on face, neck, and chest and are usually associated
with perspiration, palpitations, and anxiety, being variable
in frequency, duration, and severity, and can be the cause
for fatigue, diﬃculty concentrating, and memory lapses,
symptoms that have also been observed during menopause
transition. The cause for menopause-associated vasomotor
symptoms is not completely understood, although some the-
o r i e sh a v eb e e np r o p o s e d[ 8, 9].
Vaginal atrophy is also a common symptom during men-
opausetransition.Duetolossofestrogens,vaginaliningmay
become thinner and dryer, and the pH also changes, making
the vagina more susceptible to infections. Those alterations
can aﬀect sexual function and quality of life [10].
Others menopause-associated complications include in-
creased cardiovascular risk (see below), osteoporosis [11]
and body weight gain, which can all be a combination of
changes in hormone levels and aging.
Increase in body weight is another characteristic associ-
ated with menopause. Although it is known that the meta-
bolic rate decreases with aging, the increase in body weight
and visceral adipose tissue accumulation after menopause
havebeenassociatedwithovarianhormonewithdrawal[12].
It has been shown that, in abdominal adipocytes, estrogen
regulates the expression of lipoprotein lipase (LPL) and
hormone-sensitive lipase (HSL) [13]. In hepatocytes, estro-
gen regulates the synthesis of structural apolipoproteins
for very low-density lipoproteins (VLDLs) and high-density
lipoproteins (HDLs) and decreases the synthesis of hep-
atic lipases [14]. By regulating lipidogenesis in adipocytes
and hepatocytes, estrogen modulates lipid concentration in
plasma. The withdrawal of estrogens during induced or nat-
ural menopause leads to several lipid metabolism disorders.
For example, dyslipidemia was also observed in bilateral
oophorectomized in women [15]. Abdominal accumulation
of adipose tissue and associated dyslipidemia are important
components of a group of metabolic irregularities strongly
related with increased cardiovascular risk in the menopausal
woman.
2.CardiovascularDiseasein
Women during Menopause: The Role of
Hormone Replacement Therapy
2.1. Clinical Data: What Do We Know? Cardiovascular dis-
ease (CVD) is a multifactorial disease. Both bad lifestyle
including inappropriate diet, sedentary life, smoking and
drinking, and determined factors (e.g., aging, sex, genotype,
and menopause) inﬂuence CVD [16, 17]. The impact of
CVD on overall mortality in westernized countries is enor-
mous,accountingforupto30%ofalldeathsworldwide.The
deﬁnition of CVD includes four major groups of diseases:
coronary heart disease (CHD) disclosed by angina pectoris,
myocardial infarction, heart failure, and coronary death,
cerebrovascular disease such as stroke or transient ischemic
attack, clinically evident peripheral artery disease, aortic
atherosclerosis, and thoracic or abdominal aortic aneurysm.
What is less known is that CVD is the leading cause of
death in women, with more deaths than all other causes
combined yearly [18]. Various studies showed a growing risk
for CVD in menopausal women due to negative changes inJournal of Lipids 3
metabolism and hemodynamic parameters [16]. According
totheguidelinesoftheNationalCholesterolEducationProg-
ram (NCEP) [19], the American Heart Association (AHA),
and the American College of Cardiology (ACC) [18, 20],
evaluation of CVD risk factors in women must include a
personal CHD history, age over 55, family history of pre-
mature CHD, diabetes mellitus, dyslipidemia, hypertension,
personal history of peripheral artery disease, and smoking.
Guidelines for prevention of CVD in women were ﬁrst
publishedin1999bytheAmericanHeartAssociation(AHA)
[21].Oneconsequenceofsuchincreasedattentiontogender-
related health problems, is awareness of CVD as the leading
cause of death among women has nearly doubled since 1997
[22]. The impact of menopause should be taken into account
when discussing CVD, and this aspect has been the matter of
debate [23].
Premenopausal women have a lower incidence of CVD
when compared to men with the same age-range. Whereas
CHD is sporadic in premenopausal women [24], the inci-
dence of myocardial infarction increases with age in both
sexes, but occurs later and after menopause [24]. Estrogen
lossduringmenopausecausesnegativeeﬀectsonmetabolism
and cardiovascular function [25], and the progression to
menopause with the changes in estrogen levels decreases or
cancels the women advantage versus men [26–29].
Postmenopausal women have a higher risk of coronary
artery disease, atherosclerosis, and all causes of mortality
[29]. A consequence of this gender-related trend is that the
postmenopausal state is acknowledged as a risk factor for
CHD, with a weight similar to that of male sex [30]. Further-
more, an early natural menopause appears to be associated
with increased risk of CVD [31, 32], even in non-smokers.
Indeed, menopause is associated with increased total se-
rum cholesterol, triglycerides, and ﬁbrinogen, as well as with
a decrease in high-density lipoprotein (HDL) cholesterol.
A plausible explanation is that menopause is believed to
be a result of ﬂuctuations in hormonal status, primarily
a deﬁciency in estrogen [33]. Whether other contributing
factors may have a role on CVD after menopause, is less
clear and diﬃcult to demonstrate. The transition from pre-
menopausal phase to menopause, for example, may induce a
weight gain responsible for increased in blood pressure, total
cholesterol,low-densitylipoprotein(LDL),triglycerides,and
fasting insulin [33]. What should be mentioned is that aging
per se can be more important than menopause itself for a
number of CHD risk factors. In the SWAN study (Study
of Women’s Health Across the Nation) [34], changes in
traditional risk markers of CHD were evaluated in three
diﬀerent stages: before, within a year, and after the ﬁnal
menstrual period within a multiethnic group (African,
American, Hispanic, Japanese, or Chinese and Caucasian
women). Changes due to menopause were only represented
by total cholesterol, low-density lipoprotein cholesterol,
and apolipoprotein B. By contrast, chronological aging was
responsible for changes in the other risk factors with a linear
model.Manyotherpotentialfactorsmightbealsoimplicated
in the sex diﬀerences in coronary heart disease [35]. The
possibility that heart disease risk determines menopausal age
rather than the inverse has already been proposed [36].
Oxidative stress plays a role in hypertension, hypercho-
lesterolemia, diabetes, and promoting CVD [37]. The for-
mation of free radicals leads to cellular oxidative stress with
a contribution to the ﬁrst step of endothelial damage and
theprogressiontoatheroscleroticlesion.Theperpetuationof
the process induces the ﬁnal events of CVD, which appears
to be linked to some oxidative stress biomarkers [38, 39].
Oxidative stress appears to be an emerging factor also in
the pathophysiology of CVD in menopausal women. Studies
haveshownthatduringmenopausetheriskofCVDincreases
at the same time of a rise in oxidative status [40, 41].
It is still unclear if the type of menopause (surgical or
natural) can have a role on cardiovascular risk. The Nurses’
Health Study (1987) demonstrated that the risk of CHD was
higher in patients undergoing bilateral oophorectomy com-
pared with natural menopause. An estrogen-replacement
therapy could prevent this eﬀect[42]. In a later study, carotid
artery intima-media thickness showed a positively associa-
tion with years elapsed since menopause; however, according
to this marker of subclinical atherosclerosis, women with
natural menopause presented no diﬀerence compared with
those who had surgical menopause [43]. Indeed, men
with the common estrogen receptor alpha (ESR1) c.454-
397CC genotype have a major risk of myocardial infarction,
suggesting the potential linkage between estrogen receptors
and CVD susceptibility. In this respect, a variation in
estrogen receptor could clarify the contrasting results of
hormone therapy on CVD susceptibility in women [44]. The
apparent protective eﬀect of hormone replacement therapy
(HRT) has been a matter of debate for several years [45–
47]. Prevention of CHD and osteoporosis in menopausal
women was originally achieved by exogenous estrogen plus
progestin, assuming a protective eﬀect of estrogen on the
heart. Additional eﬀects included a protective eﬀect on
the bone and on colon cancer [48–52], despite increasing
incidence of breast cancer [53, 54]. Two landmark studies,
however, changed this view. The Women’s Health Initiative
(WHI) Estrogen plus Progestin (E+P) trial in 2002 showed
no protection for CHD and conﬁrmed the increased risk in
breast cancer and thromboembolic disease [55].
Two years later the WHI Estrogen Alone trial conﬁrmed
the lack of eﬀect on CHD while suggesting a trend for
decreased breast cancer, with a rise in stroke and venous
thromboembolic disease. A nonsigniﬁcant protective eﬀect
on CHD was seen in the younger women (ages 50 to 59)
[56]. The public consequence was that hormone therapy was
abandoned or was conducted with lower doses [57].
The possibility that CHD risk is lowered by earlier hor-
mone therapy after menopause should also be considered,
although results are not conclusive [58]. Whether hormone
replacement therapy results in either increased or unchanged
risk for stroke, is also a matter of debate [56]. Of note, recent
guidelines do not identify estrogen therapy for the primary
or secondary prevention of CHD [59, 60].
2.2. Animal Models: Helping to Deﬁne the Role of Estrogens.
Although the WHI and the Heart and Estrogen/progestin
Replacement Studies (HERS) showed no CVD protection
resulting from HRT, several animal studies have suggested4 Journal of Lipids
an important cardioprotective role for estrogens against
heart failure [61], mediated by a genomic or a nongenomic
estrogen-receptor-mediated signaling pathway(see[62]f o ra
review).
Tumor necrosis factor-alpha (TNF-α)h a sb e e nr e p o r t e d
as an important factor during I/R injury and ischemia pre-
conditioning. In a Langendorﬀ-perfused rat heart model,
estrogen reversed the deterioration of heart hemodynamics
induced by TNF-α treatment [63]. Several evidences have
beendemonstratedthatstromalcell-derivedfactor1(SDF-1)
is increased in ischemic hearts and induced cardioprotection
[64]. A higher expression of myocardial SDF-1 was observed
infemaleratsinresponsetoI/Randtheincreasedmyocardial
SDF-1 production in female hearts was due to estrogen-
estrogen Receptor α (ERα) interactions [65]. In C57BL/6J
malemice,estrogenalsoinducedcardioprotectionafteracute
myocardial infarction through a decreased activity of matrix
metalloproteinase-9 and increased Akt-Bcl-2 antiapoptotic
signaling [66]. In a Langendorﬀ isolated perfused rat
heart model, estrogen increased the perfusion pressure and
coronary resistance through activation of L-type calcium
channels [67].
Estrogen-relatedreceptoralpha(ERRα)isatranscription
factor for some myocardial mitochondrial enzymes, essential
tomaintaincardiacenergyreserves.Adecreaseinmyocardial
ERRα,regulatedbythemetabolicsensorAMP-activatedpro-
tein kinase alpha 2 (AMPKα2), was recently reported during
congestive heart failure [68]. Proteins from the intracellular
lipinfamilyarealsoinvolvedinmetabolismregulation.Itwas
reported that lipin 1 is the principal protein of this family in
myocardium and is also regulated by ERRα [69].
The lack of CVD protection observed during HRT has
been proposed to be related with alterations in sex hor-
mone synthesis and metabolism that can occur during ag-
ing, and can aﬀect the hormone environment in postmeno-
pausal women. Also age-related changes in vascular estrogen
receptors (ERs) subtype, structure, expression, distribu-
tion, and the signaling pathway in the endothelium and
vascular smooth muscle, preexisting CVD conditions, and
structural changes in blood vessels architecture have been
suggested as possible causes for the failure of HRT in
CVD [70]. It also should be noticed that HRT is not
only composed by estrogens, but also by a combination of
estrogenandprogesterone.Arecentstudydemonstratedthat
a combination of 17-α-estradiol and medroxyprogesterone
acetate aggravates chronic heart failure after experimental
myocardial infarction, which can also explain the results
from previous studies including WHI and HERS [71].
3.CardiacMitochondrialFattyAcid
Beta-Oxidation in Health and Disease:
W h e r eDoe sM e n o p aus eS t an d ?
The heart is one of the organs with the highest energy
demand in the body, which is hardly surprising due to
high energetic input required by the contractile apparatus.
Although the heart is considered an omnivorous organ due
to the fact that it can use several substrates for energy
generation, including glucose, amino acids, lactate, and
ketone bodies, fatty acids are the favored fuel for the cardiac
muscle [72, 73]. In fact, the adult heart generates between
50–70% of its ATP from fatty acid beta-oxidation, which
occurs mainly in mitochondria [72], possesses an elaborate
system to import and process fatty acids of diﬀerent lengths
[72, 74]. In fact, in itself, mitochondrial function is one
among diﬀerent factors that impact the ﬂux of fatty acid
beta-oxidation. Others include the fatty acid supply itself,
which is modulated among other factors by diet, competing
substrates for the cardiac tissue, the energy demand and
oxygen availability, and the regulation at a nuclear or
allosteric level of enzymes which are involved in all steps of
fatty acid uptake, esteriﬁcation, and metabolism [72].
Fatty acids can be transported in the plasma as free fat-
ty acids (FFAs) conjugated with albumin or as part of tri-
acylglycerol (TAG) contained in chylomicrons or very-low
density lipoproteins (VLDLs) [75, 76]. FFA concentration
in the plasma is highly variable, depending not only on the
diet, but also on the developmental state of the organism
and if any pathology is present. For example, the amount
of FFA in the plasma is known to greatly increase during
myocardial infarction [77] and diabetes [78], which leads to
an augmented cardiomyocyte FFA uptake and accumulation,
since the concentration of FFA in the plasma is a major
determinant for these two events [72]. Regardless of the
mechanism underlying an acute or chronic accumulation
of FFA in the plasma (reviewed in [72]), the end result
of cardiomyocyte cytosolic accumulation of fatty acids can
diﬀer, depending on a wide range of factors.
The ﬁrst step after entering the cardiomyocyte is con-
version to CoA esters, through the action of fatty acyl CoA
synthase (FACS). Fatty acid uptake by cells is made by
membrane proteins with high aﬃnity for fatty acids [79, 80],
namely, the fatty acid translocase (FAT/CD36), the fatty
acid binding protein (FABPpm) and a variety of fatty acid
transport proteins (FATPs), as well as by simple diﬀusion of
fatty acids through either the phospholipid bilayer or a pore
or channel formed by one or more of the referred fatty acid
transporter proteins [81]. Upon entering the cell, the rate
of utilization is governed by a variety of factors, including
malonyl-CoA, the ratio acetyl-CoA/CoA and the availability
of other substrates, namely, glucose, lactate, and ketone
bodies that can compete with free fatty acids as a source
of acetyl-CoA [79]. Long-term regulation of uptake and
utilization requires alterations in expression rates of genes
encoding for fatty acid handling proteins [82]. Free fatty
acids can also by themselves modulate the expression of such
genes via nuclear transcription factors such as peroxisome
proliferator-activated receptors (PPARs) [83].
Mitochondrial beta-oxidation of long-chain fatty acids
starts with its association with CoA, forming acyl-CoA es-
ters that are transported into mitochondria by carnitine
palmitoyl transferase I (CPT-I). Beta-oxidation produces in
each round one NADH, one FADH2 (as part of an enzymatic
complex), and one acetyl-CoA, which is further oxidized in
the Krebs cycle to CO2, with the concomitant further gen-
eration of three NADH, reduced FAD co-factor in succinate
dehydrogenase complex, and one GTP. NADH, via NADHJournal of Lipids 5
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Figure 2: Transport of fatty acids from the cytoplasm to the mitochondrial matrix for oxidation. Following activation to acyl-CoA,
CoA is exchanged for carnitine by carnitine palmityl transferase (CPT-I), which is then transported to the inside of the mitochondria
where a reversal exchange takes place through the action of carnitine acylcarnitine translocase (CPT-II), and beta-oxidation machinery
initiates its activity, producing reducing equivalents that feed the electron transport chain. More details are available in the text. CAT:
Carnitine Acylcarnitine Translocase, FFA: free fatty acid, ACS: Acyl-coA synthase, ETC: electron transport chain, IMM: inner mitochondrial
membrane, OMM: outer mitochondrial membrane, coA: coenzyme A, ATP: adenosine triphosphate, ADP: adenosine diphosphate, and
AMP: adenosine monophosphate.
dehydrogenase, and succinate dehydrogenase deliver elec-
trons to the remaining electron transport chain complexes
which contribute to the generation of a proton gradient used
tosynthesizeATP(Figure 2).Throughoutthiswholeprocess,
several regulation mechanisms can operate, starting with the
transport of the acyl chain to the mitochondrial matrix and
ending at the accumulation of end products of the oxidation
process, namely, reducing equivalents and ultimately ATP
levels. The transport process is considered a major player
in the control of the ﬂux through beta-oxidation [84],
mostly in intact muscle, since levels of malonyl-CoA are kept
considerably high. With this type of control, it is possible for
the tissues to rapidly adapt to diﬀerent metabolic demands,
such as in muscles [84]. An inhibition of fatty acid beta-
oxidation, which as mentioned can occur at several stages,
willultimatelyresultinfreefattyacidintracellularaccumula-
tionwhichsubsequentlywillberesponsibleforpoorremoval
offattyacidsfromplasmainanyoftheirformsoftransporta-
tion. In fact, a possible role has been attributed to female sex
hormones in the development of fatty liver pregnancy on the
basis of their eﬀect in the reduction of mitochondrial fatty
acid oxidation [85] and in regulating cellular energy balance
in vivo by regulating the expression of the medium chain acyl
coenzyme A dehydrogenase (MCAD) gene [86].
Besides mitochondrial oxidation, long-chain fatty acyl
coA can also be used for the synthesis of intermediates,
including TAG, diacylglycerol (DAG), and ceramide [72, 87].
Under normal intracellular concentrations, these interme-
diates are stored and/or channeled to diﬀerent biosynthetic
pathways, including biomembrane synthesis. If alterations
in normal fatty acid homeostasis occur, which can originate
from excessive plasma FFA content or from enhanced
FACS expression and/or activity, long-chain fatty acyl coA
derivatives can accumulate in cells. Depending on the tissue,
accumulation of some of these intermediates can have dis-
tinct eﬀects. For example, it is known that excessive accumu-
lation of TAG in nonadipocyte tissues can result in diﬀerent
negative outcomes including impaired insulin signaling in
the liver and skeletal muscle [88] and apoptosis and other
metabolic disturbances in the heart [87, 89, 90]. DAG has
also been determined to cause similar eﬀects in the same
tissues [88], including increased insulin resistance observed
in a model of rodent high-fat diet [91]. It is interesting to
note that both increases in TAG and ceramide intracardiac
contentdidnotcorrelatewiththeincreasedinsulinresistance
[91].
Ceramide, by its turn, has been demonstrated in diﬀer-
ent biological models to increase apoptotic signaling in sev-
eral tissues [92–94], although evidence is scarcer for the
heart [95]. It is interesting to note that ceramide derivatives
have been involved in the triggering of the mitochondrial
permeability transition pore (MPT pore) and outer-mem-
brane permeabilization [96, 97], conditions closely linked
with mitochondrial dysfunction and cell death [98]. In6 Journal of Lipids
opposition, long-chain ceramide species have been shown
to inhibit the MPT pore [99]. The discrepancy of results
regardingceramideimplicatesthislipidspeciesinthecontrol
of mitochondrial cell death pathways.
From the short description above, it is clear that a bal-
ance between FFA cell uptake and metabolism must be
reached in order to avoid the accumulation of undesired
fatty acid metabolites. Also, increased reliance of fatty acids
as fuel for cardiac cells has undesired eﬀects, one of them
being decreased ATP synthesis, resulting from increased
ATP hydrolysis for noncontractile purposes, increased mito-
chondrial uncoupling due to increased activity/expression
of uncoupling proteins and greater proton futile cycling,
creating the so-called oxygen wasting and resulting in several
physiological complications [100–102]. Interestingly, inhibi-
tion of fatty acid metabolism is proposed to be beneﬁcial for
s o m ef o r m so fh e a r tf a i l u r e[ 103].
The important question is now where the menopausal
heart stands. As described above, menopause is a normal
consequence of the aging process in women and is accompa-
nied of important physiological and biochemical alterations.
There are several evidences in the literature that the content
in FFA in the plasma tends to increase during menopause.
One particular study performed with 4-vinylcyclohexene-
diepoxide- (VCD-) treated rats indicated that progressive
loss of ovarian function induced by VCD results in an
increase of plasma FFA, which initiated several alterations
leadingtothedevelopmentofthemetabolicsyndrome[104].
This important piece of evidence mimics what is observed in
themenopausalwomen,whereanincreaseincirculatingFFA
was measured [105]. It is also known that women experience
a characteristic increase in circulating lipids at the time of
the ﬁnal menstruation period [34], although it is diﬃcult to
evaluate the component resulting from hormonal alterations
and what is the result of the normal aging process [34,
106]. The increased FFA was partly reverted by hormone-
replacement therapy, showing that, at least in part, it is a
hormone-dependent eﬀect [105]. The role of estrogens in
fatty acid metabolism is well described and involves diﬀerent
mechanisms [107–109]. One important eﬀect is that estra-
diol promotes the channeling of FFA toward oxidation and
away from triglyceride storage (Figure 3) by upregulating
the expression of peroxisome proliferation activator receptor
deltaanditstargetsandalsobydirectlyandrapidlyactivating
AMP-activated protein kinase (AMPK). AMPK acts as a fuel
sensor that increased fatty acid beta-oxidation during higher
metabolic demands [110].
The data, although still scarce and largely spread out,
indicates that during menopause, fatty acid metabolism
is altered. The decrease in estradiol levels may result in
decreased fatty acid oxidation and increased accumulation
in the adipose tissue, with hormone replacement therapies
recovering the pre-menopausal fatty acid status quo. But is
this so straightforward? Maybe not, one important player in
fatty acid metabolism is, as described, the mitochondrion.
A proper channeling of fatty acyl-CoA and subsequent beta-
oxidation is necessary for the energy-generating process. It
is clear that a failure of mitochondrial bioenergetics causes
an unbalance in fatty acid metabolism, which may result
in the accumulation of fatty acyl-CoA esters in the cytosol
of cardiomyocytes. This phenomenon could result in a
larger channeling of fatty acyl-CoA esters to the synthesis
of the intermediates described above, including TAG, DAG,
and ceramide. It is interesting to recapitulate here that
ceramide has been involved in the induction of apoptosis
in a variety of biological models [92–94]. Although the
relationship between increased ceramide intracellular levels
in the menopausal heart and increased apoptotic signaling
is still to be determined, several endpoints for increased
cardiac Fas-dependent and mitochondrial-dependent apop-
tosis were identiﬁed in the hearts of bilateral ovariectomized
Wistar rats [111, 112]. A logical question would be if
there is a possible relationship between intracellular lipid
metabolism alterations resulting from ovariectomy and
enhanced apoptotic signaling in the heart.
Decreased fatty acid oxidation by mitochondria occurs
in a variety of situations, ranging from xenobiotic-induced
toxicity to several pathologies. There are many fatty acid
oxidation disorders identiﬁed in humans, and which aﬀect
organs as diﬀerent as muscle [113]a n db r a i n[ 114], which
result in altered fat deposition and mitochondrial beta-
oxidation. Defects are commonly present in the mitochon-
drial machinery that shuttles long-chain fatty acid metabo-
lites to mitochondria, resulting in decreased beta-oxidation
[113]. Several xenobiotics also alter fatty acid metabolism in
diﬀerent organs [115], examples are ﬂuorochemicals [116]
and the antibiotic tetracycline [117] in the liver. As for
the heart, it is now becoming increasingly recognized that
alterations in fatty acid uptake and/or beta-oxidation can
result in the so-called fatty heart, a largely unrecognized
entity for a long time, and which, as described has important
cardiovascular complications [89, 118]. This subject will
deserve more attention in the future.
It has been proposed that mitochondrial function in
the heart decreases with the progression of aging. Alter-
ations include loss or oxidation of cardiolipin, a tetra-acyl
phospholipid involved in the activity of many oxidative
phosphorylation enzymes including complex I [119–121].
This presents a clear determinant of loss of mitochondrial
function and also represents a phenotype of mitochondrial
membrane aging which impacts both the bioenergetics and
several signaling pathways to and from mitochondria.
It is also known that aging-dependent cardiac mitochon-
drial eﬀects are more speciﬁc to interﬁbrillar mitochondria,
which is the subpopulation responsible for the majority of
energy supply to the myocardium [122, 123]. Such altera-
tions include decrease respiratory complex activity and in-
creased oxidative stress, while a decreased capacity for beta-
oxidation has also been demonstrated in an animal model
for aging due to alterations in carnitine palmitoyltransferase
I which were suspected to originate from a decrease in
cardiolipin content [123]. Mitochondrial “power” in the
h e a r ti st h u sa ﬀected with aging [124], which is further il-
lustrated by a decrease in the nuclear control of mitochon-
drialbiogenesisandfunction[125]andbyincreasedmtDNA
deletions frequency found in the aged heart [126].
Adding to mitochondrial aging, per se,o n eh a st oh a v ei n
mind that other factors may be operating in the menopausalJournal of Lipids 7
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Figure 3: General scheme of the hypothesis raised by the present paper. It is proposed that menopause, as a condition natural to the normal
aging process, is accompanied by speciﬁc mitochondrial alterations (bottom red box, arrow with a dark cloud) which decrease their ability
to cope with an increased ﬂux of long-chain fatty acyl CoA, resulting from augmented plasma levels. Inability to process fatty acyl CoA may
result in accumulation of fatty acid intermediates including tri- and diacylglycerol, as well as ceramide, which causes myocardial lipotoxicity
and may even result into activation of apoptotic signaling. The cardiovascular risk increases under these circumstances, which is fueled by
other coexisting pathological conditions or by pharmacological interventions that present toxicity to the cardiovascular system. Estradiol
(represented by green arrows) has been proposed to increase fatty acid oxidation by mitochondria, decreasing the ﬂux through other
biosynthetic pathways, preventing the potential accumulation of deleterious metabolites and increasing fatty acid-derived mitochondrial
ATP production.
woman that can contribute to altered mitochondrial func-
tion and result in disrupted fatty acid metabolism. For
example, the incidence of diabetes, and obesity increases
during menopause [127], which also contributes to accel-
erate mitochondrial dysfunction [128–130]. By its turn, the
menopausal woman may be under treatment with diﬀerent
medications which may also aﬀect the bioenergetic eﬃcacy
of cardiac mitochondria [131, 132], especially if other con-
ditions occur at the same time.
To summarize, ageing results into a progressive degrada-
tion of mitochondrial capacity in the heart, which, in combi-
nation with hormonal alterations resulting from menopause
anditsassociatedalterationsinlipidproﬁle,mayresultintoa
progressive decrease in lipid oxidation in mitochondria and
increased lipid storage in adipocytes and formation of fatty
acyl intermediates in the cytosol of cardiomyocytes (Figure
3). The development of insulin resistance, diabetes and
obesity can be several faces of the same coin, the increased
lipotoxicity in the cardiomyocyte of the menopausal woman.
This is a clear avenue for research that still is largely unex-
ploredanddeservesattentionsincemenopauseisacondition
that aﬀects an increasingly number of women, as the general
population is progressively aging.
If the hypothesis put together in this paper is correct,
then prophylactic measures that improve mitochondrial ca-
pacity in menopausal women would contribute to decrease
cardiovascular risk. In fact, besides hormone replacement
therapy, which replenishes estrogens and reequilibrates li-
pid homeostasis, other cotherapies may help improve the
lipid proﬁle in the menopausal woman through diﬀerent
mechanisms.Forexample,enduranceexercisehasbeendem-
onstrated to increase mitochondrial capacity in the heart
[133, 134]. In a menopausal setting, twelve weeks of endu-
rance exercise have been demonstrated to provide some
beneﬁts in increasing lipid oxidation, besides improving
other cardiorespiratory parameters [135, 136]. Carnitine,
which is essential to long-chain fatty acid beta-oxidation, has
been shown to recover some of skeletal muscle function and
inhibitalterationsinovariectomizedrats[137].Nevertheless,
to the best of our knowledge, no work on the impact of
carnitine on lipid proﬁle and oxidation in the menopausal
heart has been provided.8 Journal of Lipids
Cardiac oxidative stress after ovariectomy has also been
observed in animal models [138] although evidence for in-
creased oxidative stress in the cardiovascular system is scarce.
Estrogens per se act as antioxidants, although it is still un-
clear if estrogen supplementation during menopause is
completely without risks for the cardiovascular system [139,
140].Also,itisunclearsofarifantioxidantsupplementations
wouldimprovemitochondrialﬁtnessinmenopausalwomen.
Finally, an interesting alternative was proposed by Zern et
al. [141]. Lyophilized grape powder was given to a group
of postmenopausal women for 4 weeks. The powder was
enriched in phytochemicals such as ﬂavans, anthocyanins,
quercetin,myricetin,kaempferol,andresveratrol.Theresults
showed alterations in lipoprotein metabolism, oxidative
stress, and inﬂammatory markers, which were all decreased
in the treated group. Although the heart was not speciﬁcally
targeted in the study, the results may suggest a positive im-
pact in this organ as well. Interestingly, resveratrol is
considered an activator of mitochondrial biogenesis in dif-
ferent model systems, acting through sirtuin-1-dependent
and independent mechanisms [142–144] .T h ef u t u r ewi l lt e l l
if this is a trail worth exploring.
4. Concluding Remarks
Although there are many loose ends in the story, it appears
logical to consider that progressive deterioration of mito-
chondrial function in the aging woman with menopause
contributes to the metabolic alterations observed in the
heart, including a decreased capacity for lipid oxidation. A
decreased mitochondrial ﬂux of fatty acid beta-oxidation,
canresultinmostcasesintheaccumulationoftoxicinterme-
diatesinthecytosolandalsoofnonmetabolizedfattyacidsin
mitochondria, which leads to further deterioration of mito-
chondrial function and progressive metabolic changes that
canincreasecardiovascularrisk.Notonlythislineofthought
needstobedemonstratedinanimalmodelsandhumans,but
if true, pharmacological, or nonpharmacological strategies
must be devised to counteract this metabolic remodeling.
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